Federal budget cuts have created "a climate of anxiety" among medical researchers, says Maximilian F. Konig, a rheumatologist ...

Deucravacitinib met its primary endpoint of more than 20% improvement in ACR20 response among patients with psoriatic ...

Arthritis awareness emphasizes early detection of arthritis, a condition affecting joints, bones, and muscles. Recognizing ...

Metabolic syndrome is common in psoriatic arthritis and is a known risk factor for worse symptoms and poor treatment outcomes. This study sought to explore the syndrome's role in a more precisely ...

Psoriatic disease is a long-term (chronic) disease with, thus far, no known cure. The good news, however, is that there are ...

Dr. Michael Garshick discusses recently published recommendations for cardiovascular risk screening for patients with ...

Former Emmerdale star Adam Thomas has been open about his health battles in recent years and now has told fans that his life ...

New research emphasizes the importance of adequate-and possibly higher than currently recommended-protein intake for ...

Phase 1 data for Spyre Therapeutics, Inc.'s SPY002 & SPY072 show promise in autoimmune treatments. Advancing to Phase 2 ...

About one-third of psoriasis sufferers develop psoriatic arthritis, with swelling, tenderness and pain in joints, affecting daily activities and lifestyle. Psoriatic arthritis (PsA) is a chronic ...

Horsham: Johnson & Johnson is seeking the U.S. Food and Drug Administration (FDA) approval for the expansion of STELARA ...

APEX shows Tremfya is the first IL-23 inhibitor to slow joint damage in psoriatic arthritis, offering early, multi-domain ...